Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
Aim. To study candesartan effectiveness and tolerability in essential arterial hypertension (ГАН) and AH associated with chronic renal disease.Material and methods. This 12-week open, controlled study included 14 patients (mean age 43,4±16 years) with diagnosed ГАН (n=9) or secondary AH of renal eti...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1671 |
| _version_ | 1797882688316637184 |
|---|---|
| author | N. M. Chikhladze O. A. Sivakova E. V. Blinova T. A. Sakhnova I. P. Kolos G. N. Litonova I. E. Chazova |
| author_facet | N. M. Chikhladze O. A. Sivakova E. V. Blinova T. A. Sakhnova I. P. Kolos G. N. Litonova I. E. Chazova |
| author_sort | N. M. Chikhladze |
| collection | DOAJ |
| description | Aim. To study candesartan effectiveness and tolerability in essential arterial hypertension (ГАН) and AH associated with chronic renal disease.Material and methods. This 12-week open, controlled study included 14 patients (mean age 43,4±16 years) with diagnosed ГАН (n=9) or secondary AH of renal etiology (n=5). At baseline and after 12 weeks of candesartan therapy, office blood pressure (BP) measurement, 24-hour BP monitoring (BPM), vectorcardiography and decar-tography measurements of plasma renin activity, aldosterone, potassium levels and microalbuminuria (MAU) were performed.Results. Target BP level <140/90 mm Hg was achieved in 6 out of 14 patients (42,8 %). Additional hydrochlorothiazide (HCT) therapy increased antihypertensive effect of candesartan. On average, MAU reduced from 63,5±16,8 to 31,7±24,4 mg/d (p<0,0001).Conclusion. Candesartan therapy, especially combined with HCT, was effective in patients with mild to moderate AH, providing organo-protection. It could be recommended not only in ГАН, but also in symptomatic AH associated with chronic renal disease. |
| first_indexed | 2024-04-10T03:39:44Z |
| format | Article |
| id | doaj.art-a9974e2b154b4a4b8f4f67e299e244e7 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:39:44Z |
| publishDate | 2008-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-a9974e2b154b4a4b8f4f67e299e244e72023-03-13T07:23:16Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-12-017734381389Candesartan effectiveness in essential arterial hypertension and renal arterial hypertensionN. M. Chikhladze0O. A. Sivakova1E. V. Blinova2T. A. Sakhnova3I. P. Kolos4G. N. Litonova5I. E. Chazova6Институт клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваИнститут клинической кардиологии им. А.А. Мясникова ФГУ РК НПК Росмедтехнологии, г. МоскваAim. To study candesartan effectiveness and tolerability in essential arterial hypertension (ГАН) and AH associated with chronic renal disease.Material and methods. This 12-week open, controlled study included 14 patients (mean age 43,4±16 years) with diagnosed ГАН (n=9) or secondary AH of renal etiology (n=5). At baseline and after 12 weeks of candesartan therapy, office blood pressure (BP) measurement, 24-hour BP monitoring (BPM), vectorcardiography and decar-tography measurements of plasma renin activity, aldosterone, potassium levels and microalbuminuria (MAU) were performed.Results. Target BP level <140/90 mm Hg was achieved in 6 out of 14 patients (42,8 %). Additional hydrochlorothiazide (HCT) therapy increased antihypertensive effect of candesartan. On average, MAU reduced from 63,5±16,8 to 31,7±24,4 mg/d (p<0,0001).Conclusion. Candesartan therapy, especially combined with HCT, was effective in patients with mild to moderate AH, providing organo-protection. It could be recommended not only in ГАН, but also in symptomatic AH associated with chronic renal disease.https://cardiovascular.elpub.ru/jour/article/view/1671артериальная гипертониякандесартанорганопротекциямикроальбуминурия |
| spellingShingle | N. M. Chikhladze O. A. Sivakova E. V. Blinova T. A. Sakhnova I. P. Kolos G. N. Litonova I. E. Chazova Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension Кардиоваскулярная терапия и профилактика артериальная гипертония кандесартан органопротекция микроальбуминурия |
| title | Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| title_full | Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| title_fullStr | Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| title_full_unstemmed | Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| title_short | Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| title_sort | candesartan effectiveness in essential arterial hypertension and renal arterial hypertension |
| topic | артериальная гипертония кандесартан органопротекция микроальбуминурия |
| url | https://cardiovascular.elpub.ru/jour/article/view/1671 |
| work_keys_str_mv | AT nmchikhladze candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT oasivakova candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT evblinova candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT tasakhnova candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT ipkolos candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT gnlitonova candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension AT iechazova candesartaneffectivenessinessentialarterialhypertensionandrenalarterialhypertension |